GSK: Jemperli Trial Continues to Show Unprecedented Results With No Evidence of Disease in 100% of Patients With Locally Advanced Mismatch Repair Deficient Rectal Cancer
June 04, 2024
June 04, 2024
LONDON, England, June 4 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on June 3, 2024:
GSK plc (LSE/NYSE: GSK) today announced updated, longer-term results from the phase II supported collaborative study with Memorial Sloan Kettering Cancer Center (MSK) evaluating Jemperli (dostarlimab) as a first-line treatment--as an alternative to surgery--for mismatch repair deficient (dMMR) locally advanced rectal cancer. The trial showed an u . . .
GSK plc (LSE/NYSE: GSK) today announced updated, longer-term results from the phase II supported collaborative study with Memorial Sloan Kettering Cancer Center (MSK) evaluating Jemperli (dostarlimab) as a first-line treatment--as an alternative to surgery--for mismatch repair deficient (dMMR) locally advanced rectal cancer. The trial showed an u . . .